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Summary
The Unit of Oncohematology and Bone Marrow Trans-
plantation (BMT) was arranged on basis of the Repub-
lican Research Center of Hospital Emergencies SC (As-
tana, Republic of Kazakhstan) in August 2010. Since 
July 2014, a Clinical Department with 69 beds was ar-
ranged, and National Research Center for Oncology and 
Transplantation SC was arranged. From 2010 to 2016, 
the modalities of hematopoietic stem cell transplanta-
tion have been advanced, from autologous BMT to al-
logeneic hematopoietic stem cell transplants (HSCT) 
from matched donors (33%), and haploidentical HSCTs 
(43% in 2016), a total of 186 transpants. Bone marrow 
was used as a source of stem cells in 71 cases (71 do-
nors for allo-HSCT in 69 recipients), whereas peripheral 
stem cells were harvested in 73 cases (15 donors for 15 
recipients of allo-BMT, and 58 marrow harvests for au-
tologous BMT).
In particular, our BMT clinic and Bone Marrow Donor 
Registry developed with invaluable support and contri-
bution by the leading specialists from R. Gorbacheva 
Memorial Research Institute of Children Oncology, He-
matology and Transplantation at the St. Petersburg. This 
system of education and training allowed to arrange an 
effective HSCT structure within 3 years. This assistance 
was performed in order to consult severe patients, ar-
range optimal transplantation regimens, analyze difficult 
clinical cases, perform master classes and conferences. 
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Introduction 
The Unit of Oncohematology and Bone Marrow Transplan-
tation (BMT) was arranged on basis of the Republican Re-
search Center of Hospital Emergencies SC (Astana, Republic 
of Kazakhstan) in August 2010, using previous clinical expe-
rience of the regional hematologists. At the beginning, our 
unit consisted of ten hospital beds for chemotherapy of leu-
kemia and lymphomas. First bone marrow transplantation 
in Kazakhstan was performed just on the basis of our spe-
cialized unit. Time sequence of our main advances is shown 
in Table 1. 
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Table 1. Main steps in development of Oncohematology Unit
02.08.2010 Inauguration of the Department
29.12.2010 Auto-HSCT in myeloma disease
07.06.2011 Allogeneic HSCT, related
08.06.2011 Autologous HSCT in lymphoma
09.09.2011 Haploidentical HSCT
22.09.2013 Opening transplantation unit (6 beds)
02.09.2014 Allogeneic HSCT from unrelated donor
Invaluable support and contribution to the development 
of the BMT Unit should be mentioned. Our activities were 
supported by Professor Boris Afanasyev, Director, R. Gor-
bacheva Memorial Research Institute of Children Oncolo-
gy, Hematology and Transplantation at the St. Petersburg I. 
Pavlov State Medical University. Several leading specialists 
from the Gorbacheva Institute, e.g., Professor Alexander D. 
Kulagin, Dr. Sergey N. Bondarenko, Dr. Vladimir N. Vavilov 
worked hardly at Astana, in order to consult severe patients, 
arrange optimal transplantation regimens, analyze difficult 
clinical cases, perform master classes and conferences. This 
collaboration has been sufficiently promoted by Dr. Irina 
Pivovarova whose contribution to these advances should be 
highly evaluated.
Since 01.03.2013, the Department was rearranged to the 
Unit of Hemoblastoses, Hematopoietic Aplasias and BMT, 
followed by extension to 25 beds, with appropriately trained 
staff. The unit is a part of Hematology and Transfusiology 
Department.
Deep renovation of the hospital building (April to September 
2013) resulted into opening of aseptic wards with laminar air 
flow, including BMT unit with six beds and an intensive care 
unit of four hospital beds. 
In September 2013, the Institute of Children Oncology, He-
matology and Transplantation (St. Petersburg, Russia), to-
gether with our Department, performed the VII Memorial R. 
Gorbacheva International Symposium with a main topic: He-
matopoietic Stem Cell Transplantation in Children and Adults. 
This event has promoted further development of BMT in Re-
public of Kazakhstan, and broadening of international coop-
eration in the field. Due to these advances, Kazakhstan first 
appeared at the EBMT map, with a total of 46 transplants in 
2013 (Fig. 1). The Memorial Symposium attracted prominent 
specialists from Europe and USA (Fig. 2, 3).
Figure 1. Allogeneic stem cell transplants per 10,000,000 inhabitants: an EBMT map for 2013 (EBMT Report, 2013).
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Figure 2. Participants at the VII R. Gorbacheva Memori-
al International Symposium in Hematology and trans-
plantation in Astana (September 2013).
Figure 3. International team of hematologists visiting 
the new BMT Department in Astana (September 2013).
Since July 4, 2014, a Clinical Department with 69 beds was 
arranged, and the Centre was renamed to the National Re-
search Centre for Oncology and Transplantation SC. An on-
cohematological and BMT Department consisted of a Trans-
fusion Unit and Oncohematology Unit with an intensive care 
ward (4 beds). 20.09.2016, the Department was rearranged 
once again, with a Unit of Oncohematological Resuscitation 
and Intensive Care for 6 beds established.
Clinical activities
Composition of hematological disorders treated at the De-
partment changed over years, however, with acute leukemias 
(AL) taking a leading place (54.8%). Meanwhile, this ratio 
is increased by 10% in 2015, as compared to 2013, with in-
creased admittance of the patients with acute lymphoblastic 
leukemias (increase by 16.6% against 2013), mainly, due to 
introduction of continuous treatment protocols, including 
high-dose consolidation phase.
Since 2016, we noted higher admission for the patients with 
acute promyelocytic leukemia, due to improved diagnostics 
of this leukemia type, e.g., molecular genetic studies per-
formed by FISH assays at the laboratory in St. Petersburg 
(Russia). The most significant admittance growth was for 
bone marrow harvesting, i.e., from 9 cases in 2013 to 55 in 
2016, due to establishment and development of bone mar-
row transplantation in the country. 
Along with leukemias, we observed a significant increase in 
hospitalized patients with lymphoproliferative disorders is, 
i.e., with non-Hodgkin’s lymphomas (from 18 to 85 cases), 
Hodgkin’s disease (from 8 to 60 cases), and with multiple 
myeloma (from 23 to 100 subjects). 
Bone marrow transplantation
The first bone marrow transplantation at our clinic was per-
formed in 2010. In further time, a weak growth in HSCT was 
noted, i.e., only six in 2011 (including 1 allogeneic related, 
and 1 haploidentical; nine, in 2012 (5 allogeneic and 4, au-
tologous). Since 2013, after opening a clean block (6 beds), 
we have sufficiently increased the BMT number, i.e., 18 BMT 
(5 auto, 9 allogeneic compatible, and 4 haploidentical trans-
plants); in 2014, 46 (5 auto-, 9 allogeneic and 4 haploidenti-
cal). During next years, a stabilization in HSCT amounts is 
observed: 2015, 54 BMT, 2016, 52 BMT (Fig.4). 
Bone marrow was used as a source of stem cells in 71 cases 
(71 donors for allo-HSCT in 69 recipients), whereas periph-
eral stem cells were harvested in 73 cases (15 donors for 15 re-
cipients of allo-BMT, and 58 marrow harvests for autologous 
BMT). Poor stem cell mobilizing ability was revealed in mul-
tiple myeloma (1 case after Cyclophosphamide injections) 
and 2 lymphoma patients (DHAP-treatment). Better HSC 
mobilization was performed with Etoposide (in myeloma 
case), and in 1 patient, G-CSF was applied as hemostimulant. 
In 40 cases, both primed BM and PBSCs were infused to the 
patients. Peripheral stem cell harvesting was performed at 
the Center of Blood Transfusion in Astana by means of obso-
lete collection devices (Haemonetics MCS+). At initial steps 
of our transplantation activities, we obtained inferior stem 
cell harvests, therefore infusing additional amounts of native 
bone marrow cells. However, the situation has changed since 
2016, after installation of new equipment (Terumo Spectra 
Optia), we are able to yield sufficient amounts of peripheral 
stem cells for transplantation.
Figure 4. Total BMT figures by years at the Center of 
Oncohematology and Bone Marrow Transplantation 
(Astana, Kazakhstan). A total of 186 transplants were 
performed. Abscissa, number of transplants; ordinate, 
year of observation.
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The total amounts of HSCT do not meet appropriate Ka-
zakhstan requirements. As seen from EBMT Reports, most 
European countries perform over 100 transplants per 10 Mio 
persons. To reach this level, we should make about 200 trans-
plants annually (Table 2). 
Table 2. Estimated BMT requirements for Republic of Kazakhstan 
Type of disorder Number of primary patients Estimated BMT requirement, 
% (ЕВМТ data)
BMT requirement 
(absolute numbers)
Acute lymphoblastic leukemia 48 60 29
Acute myeloblastic leukemia 64 75 48
Aplsatic anemias 47 30 14
Myelodysplastic syndrome 48 25 12
Non-Hodgkin’s lymphoma 21 55 12
Hodgkin’s lymphoma 11 55 6
Multiple myeloma 48 65 31
Total number 152
Donor availability
The ratio of haploidentical transplants performed in our 
clinic is increased from 4 BMTs (2013) to 23 transplants in 
2015. (Fig. 5). A significant growth in haplo-HSCT is noted 
in 2015 (23 BMTs, 43%) as compared to 2014 (9 BMTs, 19% 
of total). However, a lack for HLA-identical donors was ev-
ident. According to ASBMT, about 70% of the patients with 
malignant blood disorder do not have available HLA-identi-
cal related donor [1]. A median tine for searching an unrelat-
ed donor is ca. 4 months in 50-60% of cases. This term is too 
long, due to risk of the disease relapse. 
There is an imbalance for different BMT types (Fig. 6). The 
number of auto-BMT, according to EBMT data, twice exceeds 
allo-BMT numbers. Relative number of auto-BMT (24% in 
2015) is minimal at the Oncohematology and Bone Marrow 
Transplantation Department, compared to other types. Hap-
lo-BMT (43%) and allogeneic BMT (33) are prevailing here. 
Such an imbalance occurs due to deficiency of transplantation 
beds, low activities of regions by the patient stratification and 
their selection for bone marrow transplantation.
Therefore, we considered arrangement of a local hemato-
poietic stem cell donor registry as a possible solution of this 
problem. This Registry was established in 2013. Consolidat-
ed registry of Russian Federation and Kazakh Republic have 
been created year later, and, currently, 5500 potential donors 
from Kazakhstan are introduced to this database. In 2014, a 
first HLA-identical donor from Kazakhstan was activated in 
this Registry, and the first unrelated allogeneic transplanta-
tion from this donor was performed 02.09.2016 at out De-
partment. Arrangement and advances of the Bone Marrow 
Donor Registry in our Republic are closely associated with 
collaboration and advices from Dr. Alexander L. Alyansky, 
Chief of a big Donor Registry at the R. Gorbacheva Research 
Institute of Children Oncology, Hematology and Transplan-
tation (St. Petersburg).
Figure 5. Ratios of different transplant types.
Figure 6. Time dynamics of BMTs by several years, with 
respect to the BMT types.
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Clinical results of BMT procedures
In 2015, we have performed analysis of total survival among 
the BMT patients (Fig. 7). This analysis shows a significantly 
higher total survival in a group of patients after allo-BMT 
performed in the 1st remission, as compared to survival in 
the group after allogeneic BMT carried out in the absence 
of remission, i.e., 59% vs 20%. Overall survival after haploi-
dentical BMT is also higher in the patients transplanted in 1st 
remission, as compared to the patients, undergoing BMT out 
of remission (41% vs 23%). 
Figure 7. Total survival after allogeneic BMT and haplo-BMT in the patients with acute leukemias dependent on the 
state of disease by the time of transplant.
Overall survival (OS) was also determined in a group of pa-
tients with acute myeloblastic leukemia. We compared 3 pa-
tient groups, Group1, patients receiving chemotherapy only; 
Group 2 obtained BMT in remission, and Group3, patients 
receiving an off-remission BMT (Fig.7). Overall survival 
among patients from the 2nd group was sufficiently high-
er than for groups 1 and 3, i.e., 10% vs 60%. However, OS 
among the patients after BMT beyond remission was two-
fold higher than among subjects getting chemotherapy only 
(20% vs 10%).
Preliminary analysis of overall survival among acute leu-
kemia patients (observed for 30 months in haplo-HSCT, or 
40 months in allo-HSCT) has shown an important role of the 
disease status by the time of BMT, thus being in full accord-
ance with available international data. Our results should be 
further analysed for 5-year survival in a group of ≥30 pa-
tients [2, 3, 4]. 
Figure 8. Overall survival among patients with acute leukemias (AML and ALL), when performing standard chemo-
therapy (left) and allo-HSCT at our BMT Department (right). 
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Despite the arrangement of ‘clean unit’, and BMT numbers in-
creased to 54 in 2015, high requirements for transplantation 
remain in the country. E.g., according to statistical data (Table 
2), 152 patients in Kazakhstan need BMT yearly, either allo-
geneic or autologous procedure. Acute leukemias (77 BMTs 
per year) are most common at our Department, including 29 
ALL cases and 48 AML patients. Multiple myeloma takes next 
position (31 BMT annually), followed by aplastic anemia (14 
BMTs), myelodysplastic syndromes (n=12) and non-Hodg-
kin’s lymphomas (n=12), as well as Hodgkin’s lymphoma (6 
BMTs yearly). To cover these requirements, we are planning 
increase in patient places (beds), with subsequent expansion 
of the ‘clean’ space from 6 to 15 beds.
Cooperation with clinics abroad
A big contribution to development of the Oncohematolo-
gy Department and BMT activity was made by the staff of 
the R. Gorbacheva Research Institute of Children Oncology, 
Hematology and Transplantation at the First I. Pavlov State 
Medical University (St. Petersburg, Russia), having been 
provided over last years. Over 2014-2015, we have trained in 
St. Petersburg four clinicians in Hematology at a postgrad-
uate course Current Hematology and Bone Marrow Trans-
plantation; two clinical laboratory doctors for diagnostics 
of malignant blood disorders, trained a laboratory doctor 
in clinical cytogenetics. Our collaborators from Gorbache-
va Institute have teached a specialist in hematopoietic stem 
cells harvesting, treatment and cryoconservation; performed 
educational courses for 5 clinical hematolologists at the VIII 
and IX R. Gorbacheva Memorial Symposia (2014, 2015, 
St. Petersburg).
Moreover, some specialists from St. Petersburg R. Gor-
bacheva Memorial Institute performed in Kazakhstan sev-
eral seminars and master classes over 2014, e.g., in flow cy-
tometry for detection of minimal residual disease (Babenko 
Elena V., 2014); arrangement of hematological services in 
Kazakhstan (Morozova Elena V., Bondarenko Sergey N., 
Darskaya Elena I.); a 4-week tutorial concerning Basics of 
Modern Diagnostics and Treatment in Oncohematology which 
took place in Almaty (Kazakhstan). 
A special longitudinal cooperation is performed in the 
field of arrangement of a Bone Marrow Donor Registry in 
Kazakhstan Republic. A common Russian-Kazakh donor 
search platform is arranged in order to recruit bone marrow 
donors from Russian Registry for Kazakh patients.
Some other tutorials were performed in 2015, includ-
ing a school for paroxysmal nocturnal hemoglobinuria 
(Babenko E. V., Kulagin A. D., held in St. Petersburg), a mas-
ter class by E. V. Babenko concerning immune phenotyping 
of PNH markers (April 2015, Astana, Kazakhstan); an expert 
council on invasive fungal invasions in hematology (13 May, 
2015, Research Institute of Pediatrics and Children Surgery, 
Prof. K. O. Omarova, N. N. Klimko, PhD M. O. Popova). 
A tutorial “Hematopoietic stem cell transplantation in the 
children with oncohematological diseases and orphan dis-
eases” was performed on May 25-30, 2015, in Astana, led by 
Dr. S. N. Bondarenko), followed by a master class: Arrange-
ment of a Bone Marrow Donor Registry (May 26-28, 2015, 
Astanа, led by Dr. A. L. Alyansky).
Further prospectives
Future cooperation between the 1st St. Petersburg State Med-
ical I. Pavlov University and hematological institutions in 
St. Petersburg and Kazakhstan in the field of hematopoietic 
transplantation should be developed in the abovementioned 
directions:
1. Hematopoietic transplantation in pediatric practice and 
adult patients.
1) Further development of diagnostic base in oncohema-
tology (morphology, immunohistochemistry, immune 
phenotyping, cytogenetics, molecular diagnostics).
2) Unified and improved diagnostic and therapeutic pro-
tocols, in order to assess and treat tumor and non-tumor 
blood diseases.
3) Orphan dieases (diagnostics, registries, bone marrow 
transplantation, target therapy). 
2. Functioning of a common Bone Marrow Donor Registry.
Our plans for the nearest future are connected with meeting 
the requirements of Kazakh patients in transplantation assis-
tance, e.g., an increase of clinical facilities by 5 hospital beds, 
and opening a special block for therapy of lymphoprolifer-
ative disorders with 15 beds, as well as expansion of critical 
care unit to 9 beds. Increasing number of patients needs ar-
rangement of outpatient service and polyclinics.
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Опыт Астаны: отдел онкогематологии и трансплан- 
тации костного мозга, Национальный исследова-
тельский Центр онкологии и трансплантации 
Вадим М. Кемайкин, Анастасия A. Олифирович, Александр В. Колеснев, Анатолий В. Немеровченко,
Рузаль Ф. Вильданова, Ольга В. Гайнутдинова, Адия А. Тусипова, Аяужан Е. Есимбекова, Алия K. Баймурзина, 
Айзат С. Сулейменова, Ольга O. Лесечко, Гульназ Д. Ансатбаева, Мария С. Алимбетова
Департамент трансплантации костного мозга, Национальный научный центр онкологии и трансплантации, Астана, 
Республика Казахстан 
Резюме
Отделение онкогематологии и трансплантации 
костного мозга (ТКМ) было организовано на базе 
Республиканского научного центра неотложной ме-
дицинской помощи (Астана, Республика Казахстан) 
в августе 2010 г. С июля 2014 г. организован клиниче-
ский департамент на 60 коек, и было учреждено АО 
«Национальный научный Центр онкологии и транс-
плантации». С 2010 по 2016 гг. начали внедряться 
различные типы трансплантации гемопоэтических 
стволовых клеток (ТГСК) – от аутологичной ТКМ 
до аллогенной ТГСК от совместимых доноров (33% 
в 2016 г.) и гаплоидентичной ТГСК (43% от общего 
числа пересадок в 2016 г.). Всего с 2010 г. в отделе-
нии проведены 186 ТГСК. Костный мозг в качестве 
трансплантата использовали в 71 случае (71 донор 
для алло-ТГСК 69 реципиентам), тогда как пери-
ферические стволовые клетки заготавливали в 73 
случаях (15 доноров для алло-ТГСК), и 58 заготовок 
костного мозга для аутологичных ТКМ).
Особый вклад в развитие нашей клиники ТКМ и 
регистра доноров костного мозга внесли ведущие 
специалисты НИИ детской онкологии, гематоло-
гии и трансплантологии им. Р. М. Горбачевой в 
Санкт-Петербурге. Эти мероприятия по обучению 
и образованию позволили организовать эффектив-
ную структуру для ТГСК за 3 года. Такая помощь 
оказывалась по линии консультирования тяжелых 
клинических случаев, назначения оптимальных ре-
жимов трансплантации, анализа сложных клиниче-
ских случаев, в виде конференций и мастер-классов. 
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Трансплантация гемопоэтических стволовых клеток, 
организация клиники, Астана, казахстанский опыт.
